Live In Play®
Updated: 13-Apr-23 07:04 ET
TLSA:  Tiziana Life Sciences announces it plans to investigate intranasal foralumab for the treatment of Long COVID  (1.02)
  • The work is supported by foralumab's well-established role in de-activating microglia cells, a key component in the pathogenesis of this disease.
  • Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trln.
  • The role of activated microglia is well-established in the pathogenesis of Long COVID and Tiziana's first-in-class intranasal foralumab dampens activated microglia.
Cookie Preferences

Cookie Preferences

Briefing.com uses cookies to operate the site, maintain security, remember preferences, and provide subscription features. These cookies are necessary to use Briefing.com.

We also use optional analytics cookies to understand site usage and improve our services.

View Cookie Policy
Required CookiesAlways On

These cookies are necessary to operate the site and use Briefing.com.

Analytics CookiesOptional

These cookies help us understand site usage and improve our services.

If you decline required cookies, you will not be able to use the site.

Send
Chat Icon